BioSpace News Archive

Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available.

Pelvic Rehabilitation Medicine, a national leader in endometriosis care, believes that when it comes to endometriosis, conducted a study of patients who received the PRM Protocol™ before their endometriosis excision surgery.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will present at the Noble Capital Markets Virtual Equity Conference, being held June 26-27, 2024.

Sen-Jam Pharmaceutical is pleased to announce the successful completion of participant enrollment for the clinical trial of its innovative therapeutic, SJP-002C in partnership with Duke University.

RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation of multispecific ophthalmic therapies, announced the appointment of Ronil Patel as Chief Business Officer, effective immediately.

Heart Hospital of New Mexico at Lovelace Medical Center and GE HealthCare announced HHNM as the first location in the United States to install GE HealthCare’s latest Allia Image Guided System Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases.

Bold Therapeutics, a clinical-stage metallotherapeutics company, has been invited to speak at the 2024 ‘Metals in Medicine’ GRC held in Andover, New Hampshire between June 23 to 28, 2024.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces the results of the Annul General Meeting.

Moberg Pharma announces that 17,776,856 warrants of series 2023:1 were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%.

Findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 receptor agonist were reported, demonstrating semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease.